---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-034729"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:37:23.079033+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma effects 1:50 reverse stock split; trading halted on NYSE American, risk of delisting

## Summary
- Effective Aug 30, 2024, Matinas executed a 1:50 reverse stock split and reduced authorized shares from 500M to 250M.
- Trading of MTNB halted on NYSE American on Aug 27 due to low price; expects to resume split-adjusted on Sep 3 subject to exchange approval.
- If post-split share price fails to meet NYSE American requirements, exchange could suspend trading or delist the stock.
- No fractional shares issued; stockholders with fractional entitlements were rounded up to the next whole share.
- Reverse split approved by stockholders on Nov 1, 2023; Board authorized filing on Aug 20, 2024.

## SEC filing metadata
- accession: 0001493152-24-034729
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224034729/0001493152-24-034729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224034729/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-034729
- JSON: https://secwatch.observer/filing/0001493152-24-034729.json
- Plain text: https://secwatch.observer/filing/0001493152-24-034729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.